Edoxaban Management in Diagnostic and Therapeutic Procedures
Latest Information Update: 20 Feb 2024
At a glance
- Drugs Edoxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Adverse reactions
- Acronyms EMIT-AF/VTE
- Sponsors Daiichi Sankyo Inc
- 26 Oct 2022 Results of sub analysis of the Global EMIT-AF/VTE program(NCT02950168, NCT02951039) comparing the baseline characteristics, periprocedural management, and outcomes of patients who underwent major or nonmajor surgery.presented at the ANESTHESIOLOGY 2022 Annual Meeting of the American Society of Anesthesiologists
- 11 Oct 2022 Results of a sub-group analysis from two clinical studies (NCT02950168 and NCT02951039) assessing physician-guided periprocedural management of Edoxaban therapy and clinical outcomes in patients undergoing endoscopic procedures presented at the 30th United European Gastroenterology Week
- 14 Dec 2021 Primary endpoint has not been met. (Percentage of participants with major bleeding within 30 days after a planned or unplanned procedure)